Table 3 Association of CX3CR1 dynamic change in intraperitoneal lavage fluid with clinicopathological data and operative outcomes

Sex

Male/ Female

1/ 4

3/ 16

2/ 3

4/ 8

0.573

Age(years-old)

75.0 (67.0-78.0)

72.0 (69.5-77.5)

65.0 (57.0-72.0)

71.5 (70.3-73.8)

0.542

Tumor size (mm)

56.0 (45.0-70.0)

50.0 (32.5-87.5)

38.0 (18.0-40.0)

37.5 (30.0-56.3)

0.258

Comorbidities

absent/ present

1/ 4

2/ 17

1/ 4

2/ 10

0.913

Other cancer history

absent/ present

5/ 0

10/ 9

4/ 1

8/ 4

0.211

Preoperative NLR

2.20 (2.16-3.34)

2.85 (2.28-3.52)

1.69 (1.58-1.72)

2.14 (1.75-3.30)

0.123

Postoperative NLR

7.43 (5.41-25.7)

7.32 (5.83-10.1)

5.88 (5.56-8.44)

4.13 (3.54-6.14)

0.025*

Preoperative PLR

111 (80.4-131)

125 (93.7-178)

53.5 (40.6-65.0)

64.0 (51.2-115)

0.004*

Postoperative PLR

186 (182-560)

195 (173-399)

89.7 (79.0-186)

113 (83.8-167)

0.010*

CRP POD3

20.5 (10.1-23.2)

13.9 (9.84-23.9)

9.90 (8.35-14.3)

4.34 (2.94-3.0)

0.065

cT stage^a

T1-2/ 3-4

2/ 3

4/ 15

2/ 3

5/ 7

0.601

cN stage^a

N0/ 1-3

3/ 2

15/ 4

4/ 1

9/ 3

0.842

cStage^a

Stage I-II/ III-IV

2/ 3

11/ 8

3/ 2

5/ 7

0.757

Histological type

differentiated/ undifferentiated

1/ 4

11/ 8

3/ 2

7/ 5

0.457

pT stage^a

T1-2/ 3-4

2/ 3

4/ 15

4/ 1

6/ 6

0.082

pN number

1.0 (0.0-2.0)

2.0 (0.0-3.0)

0.0 (0.0-0.0)

0.0 (0.0-3.25)

0.498

pN stage^a

N0/ 1-3

4/ 1

10/ 9

4/ 1

8/ 4

0.533

pStage^a

Stage I-II/ III-IV

3/ 2

11/ 8

4/ 1

9/ 3

0.682

Lymphatic invasion

absent/ present

4/ 1

7/ 12

3/ 2

9/ 3

0.122

Venous invasion

absent/ present

3/ 2

9/ 10

4/ 1

8/ 4

0.521

Operative approach

open/ laparoscopic

2/ 3

3/ 16

2/ 3

3/ 9

0.555

Operative procedure

DG or PG/ TG

4/ 1

10/ 9

4/ 1

9/ 3

0.421

Lymphadenectomy

D1 or 1+/ D2

3/ 2

3/ 16

3/ 2

7/ 5

0.045*

Operative time (min)

294 (261-322)

259 (213-286)

306 (230-325)

234 (211-283)

0.353

Anesthesia time (min)

321 (306-370)

294 (246-324)

339 (273-365)

291 (248-333)

0.469

Bleeding (mL)

370 (50.0-615)

230 (110-375)

510 (20.0-920)

70.0 (13.8-395)

0.434

Comlplications

absent/ present

3/ 2

11/ 8

3/ 2

9/ 3

0.803

Duration of hospitalization (days)

13 (11-20)

14 (11.5-21.5)

11 (11-13)

10 (9.0-14)

0.184

Adjuvant chemotherapy

absent/ present

2/ 3

6/ 13

4/ 1

7/ 5

0.194

Recurrence

absent/ present

2/ 3

12/ 7

4/ 1

11/ 1

0.135

Recurrent style (local/ lymphatic/ hematogenous/ dissemination)

1/ 0/ 1/ 1

0/ 2/ 3/ 4

0/ 0/ 0/ 1

0/ 0/ 0/ 1

0.771